ArticleAdvances in therapy2025

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan.

Yoshikazu Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.